Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

Sonja Althammer, PhD
Published: Wednesday, Nov 16, 2016


Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.  
 
It was already known that PD-L1 by itself serves as biomarker to predict response to durvalumab.  However, researchers hypothesized that both CD8+ and PD-L1+ cells were critical for patient response to immunotherapies.
 
The study determined that the combination of CD8+ and PD-L1+ both correlated with response and improved overall survival with durvalumab. An independent study is planned to validate these results.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x